Indication: Lung Cancer
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination with AB122, and AB154 in Combination with AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Sub-indication: Non-Small Cell Lung Cancer
Line of Therapy: Front-line
Principal Investigator: Adam Lye, M.D.Norton Cancer Institute
Sponsor: Arcus Biosciences, Inc.
Email for more information: Lung-NCIResearch@nortonhealthcare.org